Welcome to our dedicated page for SBC Medical Group Holdings Incorporated news (Ticker: SBC), a resource for investors and traders seeking the latest updates and insights on SBC Medical Group Holdings Incorporated stock.
SBC Medical Group Holdings Inc (SBC) provides specialized management services for cosmetic treatment clinics across Japan. This news hub offers investors and industry observers centralized access to official corporate communications and market developments.
Track all material announcements including earnings reports, franchise network expansions, and operational updates. Our curated feed ensures timely access to press releases about marketing initiatives, staff training programs, and facility management developments relevant to the medical aesthetics sector.
Key updates cover strategic partnerships, management service enhancements, and industry leadership activities. Bookmark this page for efficient monitoring of SBC's franchise support innovations and corporate milestones within Japan's competitive cosmetic treatment landscape.
SBC (NASDAQ: SBC) announced an updated capital strategy including an effective Form S-3 registration statement and a $20.0 million share repurchase program.
The SEC declared the Form S-3 effective on December 30, 2025, enabling the company to offer up to $50 million of common or preferred stock from time to time; no securities are being sold under the shelf at this time. The Form S-3 also covers securities related to the company's business combination that closed on September 17, 2024.
The board authorized a $20.0 million repurchase program that may run through December 31, 2026, use open-market and private transactions, and may utilize Rule 10b5-1 plans; repurchases are discretionary and may be limited by debt agreements and market conditions.
SBC Medical Group Holdings (Nasdaq: SBC) announced final results of its tender offer for Waqoo, Inc. (Tokyo:4937) common shares. The offer ran from Nov 14, 2025 to Dec 12, 2025 at JPY 1,900 per share.
SBC will acquire 575,052 shares (total investment ~JPY 1,092.5 million), with settlement beginning Dec 19, 2025. The largest shareholder will transfer remaining shares off-market effective Dec 19, 2025, raising SBC’s voting-rights ownership to over 50%, making SBC the parent company of Waqoo.
SBC Medical Group (Nasdaq: SBC) entered Thailand via a Consulting Agreement with BLEZ ASIA on Nov 14, 2025 to open a dermatology-focused clinic in Bangkok’s Asok district by year-end. SBC will provide clinical protocol development, device selection, and management support while BLEZ contributes local operations, a network of 20+ pharmacies/clinics, and annual patient flows.
The move follows SBC’s Singapore launch (Nov 2024) and targets Japanese expatriates initially, with ASEAN expansion planned after validating demand. Industry data cited: Thailand aesthetic market $372.24M (2024), projected to $1.118B by 2033 (CAGR 13.51% from 2025–2033).
SBC Medical Group (Nasdaq: SBC) reported Q3 2025 results for the three months ended September 30, 2025. Q3 revenue was $43.0M (down 18% YoY) while income from operations rose to $16.0M (up 15% YoY). Net income attributable was $13.0M (up 353% YoY) and EPS was $0.12 vs $0.03 a year earlier. EBITDA was $17.0M (up 12%) with a Q3 EBITDA margin of 38% vs 28% prior year. Year-to-date revenues were $134.0M (down 17%) and YTD net income was $37.0M (down 8%). Management attributed improved profitability to lower IPO and stock-based compensation costs and cited franchise expansion and customer growth as supporting metrics.
SBC Medical Group (NASDAQ: SBC) announced that its Japanese subsidiary (the Tender Offeror) commenced a tender offer for Waqoo, Inc. on Nov 13, 2025, and will file a Tender Offer Registration Statement on Nov 14, 2025. The Tender Offer runs from Nov 14 to Dec 12, 2025 (20 business days) with a tender price of JPY 1,900 per share and an upper purchase limit of 575,000 shares. Settlement is scheduled for Dec 19, 2025.
As of the announcement the Tender Offeror holds 353,600 shares (9.49%)989,802 shares (26.58%) and will transfer those shares to the Tender Offeror at a related-party transfer price of JPY 1,445 per share (lower than the tender price). The transaction is presented as a strategic move to integrate Waqoo’s R&D and technologies into the SBC Group for clinical and regenerative-medicine development.
SBC Medical (Nasdaq: SBC) will release its Q3 2025 financial results on Friday, November 14, 2025 before U.S. market open and will discuss results on an earnings call on Monday, November 17, 2025 at 5:00 p.m. ET.
Investors must register in advance via the provided registration link to access the live conference viewing site, which will host speaker details, downloadable presentation slides available starting 10 minutes before the call, and a replay accessible through November 17, 2026. The earnings release, slides, and archived webcast will also be posted on SBC Medical's Investor Relations website.
SBC Medical Group Holdings (Nasdaq: SBC) announced the launch of its new brand, "Hada no Aozora Clinic", set to open in Tokyo on October 1, 2025. The clinic will implement a hybrid dermatology model combining insurance-covered general dermatology with private-pay aesthetic treatments.
The expansion comes amid significant growth in non-surgical procedures in Japan, which increased from 1.62 million in 2017 to 3.06 million in 2024, representing 88% of total aesthetic treatments. SBC Medical, which operates over 250 clinics globally with six million annual patient visits, aims to leverage its experience in both private-pay and insurance-based care to maintain an efficient, low-cost operating model.
SBC Medical (NASDAQ:SBC), a global provider of medical consulting and management services, has announced its participation in two major investor conferences in September 2025.
The company will present at the H.C. Wainwright Conference on September 8, with Head of IR Hikaru Fukui as the main speaker. Additionally, Director, CFO, and COO Yuya Yoshida will deliver a presentation at the Emerging Growth Conference on September 25 from 9:05 - 9:35 AM ET. During these events, SBC Medical will conduct one-on-one meetings with institutional investors.
SBC Medical Group (NASDAQ:SBC) has appointed Dr. Ewen Chee as President of Aesthetic Healthcare Holdings (AHH) and Lead Doctor for Asia Strategy. Dr. Chee, founder of Singapore's leading aesthetic medical company AHH and The Chelsea Clinic, brings over 20 years of clinical experience in aesthetic medicine.
Dr. Chee will focus on physician recruitment and training across the Asia-Pacific region. He is a certified physician of the American Academy of Aesthetic Medicine (AAAM) and has served as Co-Chair of the Asia-Pacific Thread Lift Meeting (APEM). His expertise spans various treatments including fillers, lasers, botulinum toxin, and thread lifts.
The appointment aims to leverage Singapore's position as the "Aesthetic Medicine Hub of Asia" and establish a scalable platform for SBC's expansion in the region.
SBC Medical Group (NASDAQ: SBC) reported challenging Q2 2025 financial results, with significant year-over-year declines across key metrics. Total revenue decreased 18% to $43 million, while net income fell 87% to $2.5 million. Earnings per share dropped to $0.02 from $0.20 in Q2 2024.
Despite financial headwinds, the company demonstrated operational growth with 259 franchise locations (up 36 locations YoY) and served 6.31 million customers (14% increase YoY) with a strong 72% repeat rate. The decline in financial metrics was primarily attributed to strategic shifts, including the discontinuation of staffing services, targeted divestitures, and fee structure revisions.
Management remains focused on optimizing their franchise model and transitioning to higher-margin operations despite challenges in Japan's consumer discretionary market.
FAQ
What is the current stock price of SBC Medical Group Holdings Incorporated (SBC)?
What is the market cap of SBC Medical Group Holdings Incorporated (SBC)?
